Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Novo Nordisk ... treatment known as an amylin analog — and semaglutide, the active ingredient in Wegovy. It was hoped that the drug would offer improved weight loss for patients with diabetes ...

Novo Nordisk has ... to diversify its obesity range. "Novo Nordisk is dedicated to providing improved treatment options for people living with obesity, type 2 diabetes, and other cardiometabolic ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Novo Nordisk ... diabetes treatment following CagriSema's latest results. However, Soren Lontoft, pharma equity analyst at Sydbank, told CNBC last week that there was need for a diverse range ...

There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes ... range of items, such as chairs, lamps, and other glassware. "Novo Nordisk ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Diabetes treatment has advanced since several diabetes organizations united to recommend a “time in range” target of ... MannKind, Novo Nordisk, and Sanofi. Carlson had no personal financial ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

The race is on to make the first oral weight loss medicines, but smaller US pharmacies may have already got there – if they can persuade US regulators their products are legal ...